Avidity Partners Management
$624M 13F equity value
59 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Avidity Partners Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| DNTH | DIANTHUS THERAPEUTICS INC | 2,104,184 | $205M | 32.8% |
| CGON | CG ONCOLOGY INC | 1,398,948 | $99M | 15.9% |
| ORKA | ORUKA THERAPEUTICS INC | 760,424 | $72M | 11.6% |
| JBIO | JADE BIOSCIENCES INC | 1,700,708 | $38M | 6.1% |
| ELVN | ENLIVEN THERAPEUTICS INC | 550,000 | $28M | 4.5% |
| CATX | PERSPECTIVE THERAPEUTICS INC | 6,299,999 | $21M | 3.4% |
| AKTS | AKTIS ONCOLOGY INC | 484,200 | $16M | 2.5% |
| PVLA | PALVELLA THERAPEUTICS INC NE | 70,000 | $11M | 1.7% |
| MOBI | MOBIA MED INC | 798,282 | $11M | 1.7% |
| RGEN | REPLIGEN CORP | 77,800 | $11M | 1.7% |
Track Avidity Partners Management's 13F portfolio: $624M in reported holdings, 59 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}